MiRNA-302b suppresses human hepatocellular carcinoma by targeting akt2

Molecular Cancer Research

Volumn 12, Issue 2, 2014, Pages 190-202

  Wang, Lumin ^a   Yao, Jiayi ^a   Zhang, Xiaogang ^b   Guo, Bo ^a   Le, Xiaofeng ^d   Cubberly, Mark ^e   Li, Zongfang ^c   Nan, Kejun ^b   Song, Tusheng ^a   Huang, Chen ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c Engineering Research Center of Biotherapy and Translational Medicine of Shaanxi Province   (China)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; MICRORNA; MICRORNA 302B; PROTEIN KINASE B BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENICITY; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING;

ADULT; AGED; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, NUDE; MICRORNAS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84896717410     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0411     Document Type: Article

References (44)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
2. van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer 2011;47: 1789-97.
3. Buontempo F, Ersahin T, Missiroli S, Senturk S, Etro D, Ozturk M, et al. Inhibition of AKT signaling in hepatoma cells induces apoptotic cell death independent of AKT activation status. Invest New Drugs 2011;29:1303-13.
4. Hsieh SY, Zhuang FH,WuYT, Chen JK, Lee YL. Profiling the proteome dynamics during the cell cycle of human hepatoma cells. Proteomics 2008;8:2872-84.
5. Xu N, Lao Y, Zhang Y, Gillespie DA. AKT: a double-edged sword in cell proliferation and genome stability. J Oncol 2012;2012:951724.
6. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN. Transduction of interleukin-2 antiapoptotic and proliferative signals via AKT protein kinase. Proc Natl Acad Sci U S A 1997;94:3627-32.
7. Gartel AL, Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res 2003;283:17-21.
8. Kawai H, Lopez-Pajares V, Kim MM, Wiederschain D, Yuan ZM. RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res 2007;67:6026-30.
9. Lopez-Pajares V, Kim MM, Yuan ZM. Phosphorylation of MDMX mediated by AKT leads to stabilization and induces 14-3-3 binding. J Biol Chem 2008;283:13707-13.
10. Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, et al. Activation of AKT/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol 2002;22:7831-41.
11. Maddika S, Ande SR, Wiechec E, Hansen LL, Wesselborg S, Los M. AKT-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J Cell Sci 2008;121:979-88.
12. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
13. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics: a comprehensive review.EMBOMolMed 2012;4:143-59.
14. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008;47:897-907.
15. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009;361:1437-47.
16. Kumar A. MicroRNA in HCV infection and liver cancer. Biochim Biophys Acta 2011;1809:694-9.
17. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009;28:3526-36.
18. MaS, Tang KH, ChanYP, Lee TK, Kwan PS, Castilho A, et al. miR-130b Promotes CD133(p) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010;7:694-707.
19. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 2010;107:264-9.
20. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, et al. Micro- RNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008;135: 257-69.
21. Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, et al. MiR- 222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 2010;16:867-75.
22. Ren J, Jin P, Wang E, MarincolaFM, Stroncek DF. MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med 2009;7:20.
23. Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, et al. Human embryonic stem cells express a unique set of microRNAs. Dev Biol 2004;270:488-98.
24. Barroso-delJesus A, Romero-Lopez C, Lucena-Aguilar G, Melen GJ, Sanchez L, Ligero G, et al. Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol Cell Biol 2008;28:6609-19.
25. Card DA, Hebbar PB, Li L, Trotter KW, Komatsu Y, Mishina Y, et al. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol 2008;28:6426-38.
26. Judson RL, Babiarz JE, Venere M, Blelloch R. Embryonic stem cellspecific microRNAs promote induced pluripotency. Nat Biotechnol 2009;27:459-61.
27. Lin SL, Chang DC, Ying SY, Leu D, Wu DT. MicroRNA miR-302 inhibits the tumorigenicity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res 2010;70:9473-82.
28. Murray MJ, Halsall DJ, Hook CE, Williams DM, Nicholson JC, Coleman N. Identification of microRNAs From the miR-371 - 373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am J Clin Pathol 2011;135:119-25.
29. Zhang Y, He X, Liu Y, Ye Y, Zhang H, He P, et al. microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. Oncol Rep 2012;27: 685-94.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitativePCR and the 2(-DDC(T)) Method. Methods 2001;25:402-8.
31. Luker GD, Luker KE. Luciferase protein complementation assays for bioluminescence imaging of cells and mice. Methods Mol Biol 2011;680:29-43.
32. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-9.
33. Mitchell C, Willenbring H. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc 2008;3:1167-70.
34. Lai KW, Koh KX, Loh M, Tada K, Subramaniam MM, Lim XY, et al. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer 2010;46:1456-63.
35. Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 2007;120:1598-602.
36. Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005;104:2255-65.
37. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005;26:495-502.
38. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by AKT-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001;3:245-52.
39. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005;94:29-86.
40. Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. AKT1 and AKT2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res 2009;69: 5057-64.
41. Subramanyam D, Lamouille S, Judson RL, Liu JY, Bucay N, Derynck R, et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol 2011;29:443-8.
42. Scherr M, Venturini L, Battmer K, Schaller-Schoenitz M, Schaefer D, Dallmann I, et al. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res 2007; 35:e149.
43. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137: 1005-17.
44. Vester B, Wengel J. LNA (locked nucleic acid): high-affinity targeting of elementary RNA and DNA. Biochemistry 2004;43:13233-41.